Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Richard DelGizzi"'
Autor:
Patrick R. Lawler, MD, MPH, Garen Manvelian, PhD, Alida Coppi, PhD, Amy Damask, PhD, Michael N. Cantor, MD, Manuel A. R. Ferreira, PhD, Charles Paulding, PhD, Nilanjana Banerjee, PhD, Dadong Li, PhD, Susan Jorgensen, MS, Richa Attre, PhD, David J. Carey, PhD, Kristi Krebs, PhD, Lili Milani, PhD, Kristian Hveem, MD, Jan K. Damås, PhD, Erik Solligård, PhD, Stefan Stender, MD, Anne Tybjærg-Hansen, MD, Børge G. Nordestgaard, MD, Tamara Hernandez-Beeftink, PhD, Tormod Rogne, MD, Carlos Flores, PhD, Jesús Villar, MD, Keith R. Walley, MD, Vincent X. Liu, MD, Alison E. Fohner, PhD, Luca A. Lotta, MD, Christos A. Kyratsous, PhD, Mark W. Sleeman, PhD, Michel Scemama, MD, Richard DelGizzi, MS, Robert Pordy, MD, Julie E. Horowitz, PhD, Aris Baras, MD, Greg S. Martin, MD, Philippe Gabriel Steg, MD, Gregory G. Schwartz, MD, Michael Szarek, PhD, Shaun G. Goodman, MD
Publikováno v:
Critical Care Explorations, Vol 5, Iss 11, p e0997 (2023)
OBJECTIVES:. Treatments that prevent sepsis complications are needed. Circulating lipid and protein assemblies—lipoproteins play critical roles in clearing pathogens from the bloodstream. We investigated whether early inhibition of proprotein conve
Externí odkaz:
https://doaj.org/article/9668af2bf04b4033991c97345adef80d
Autor:
Maja Di Rocco, Eduardo Forleo-Neto, Robert Pignolo, Richard Keen, Philippe Orcel, Thomas Funck-Brentano, Christian Roux, Sami Kolta, Annalisa Madeo, Judith S Bubbear, Jacek Tabarkiewicz, Małgorzata Szczepanek, Javier Bachiller-Corral, Angela M Cheung, Kathryn M Dahir, Esmée Botman, Pieter G Raijmakers, Mona Al Mukaddam, Lianne Tile, Cynthia Portal-Celhay, Neena Sarkar, Peijie Hou, Bret Musser, Anita Boyapati, Kusha Mohammadi, Scott Mellis, Andrew J. Rankin, Aris N. Economides, Dinko Gonzalez Trotter, Gary Herman, Sarah J. O’Meara, Richard DelGizzi, David M. Weinreich, George D. Yancopolous, E. Marelise W. Eekhoff, Frederick S. Kaplan
BackgroundFibrodysplasia ossificans progressiva (FOP), an ultra-rare disorder caused by mutations in the gene encoding activin A receptor type 1 (ACVR1), is characterized by painful flare-ups and cumulative heterotopic ossification (HO). Garetosmab,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c882b21013c888887c75dbb8599f68a0
https://doi.org/10.1101/2023.01.11.23284254
https://doi.org/10.1101/2023.01.11.23284254
Autor:
Su Liang, Richard DelGizzi, Tiera Drewery, An Zhao, Marcella Ruddy, Yuhuan Wang, Manoj Rajadhyaksha, Frédéric Vanhoutte, Gary Herman, John D. Davis, Eduardo Forleo-Neto
Publikováno v:
Journal of Clinical Pharmacology
We describe outcomes from the first‐in‐human study of garetosmab (a fully human monoclonal antibody that inhibits activin A) under development for the treatment of fibrodysplasia ossificans progressiva (FOP). In a double‐blind, placebo‐contro
Autor:
Ming-Dauh Wang, Melissa Simek-Lemos, Srinivasa Prasad, Olivier Harari, Ronda Rippley, Richard DelGizzi, Yan G. Ni, Stephen Godin, Andrew J Rankin, Jonathan Weyne, Morton Lori C
Publikováno v:
Blood. 132:1039-1039
INTRODUCTION: Blockade of complement factor C5 has demonstrated benefit in Paroxysmal Nocturnal Hemoglobinuria (PNH), atypical Hemolytic Uremic Syndrome and Generalized Myasthenia Gravis. We developed a human IgG4P antibody, REGN3918, that binds with